Want to see IN:APLLTD full AI Analyst Report?
Alembic Pharmaceuticals Limited (APLLTD) Ratios
Alembic Pharmaceuticals Limited Ratios
IN:APLLTD's free cash flow for Q1 2027 was $0.00. For the 2027 fiscal year, IN:APLLTD's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.76 | 1.69 | 2.12 | 1.78 | 1.67 |
| Quick Ratio | 0.79 | 0.75 | 0.99 | 0.88 | 0.73 |
| Cash Ratio | 0.08 | 0.04 | 0.08 | 0.05 | 0.04 |
| Solvency Ratio | 0.32 | 0.33 | 0.53 | 0.33 | 0.42 |
| Operating Cash Flow Ratio | 0.27 | 0.04 | 0.55 | 0.44 | 0.32 |
| Short-Term Operating Cash Flow Coverage | 0.56 | 0.07 | 1.87 | 1.14 | 0.88 |
| Net Current Asset Value | $ 14.79B | $ 15.04B | $ 14.51B | $ 10.98B | $ 9.76B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.16 | 0.08 | 0.12 | 0.10 |
| Debt-to-Equity Ratio | 0.25 | 0.24 | 0.11 | 0.17 | 0.14 |
| Debt-to-Capital Ratio | 0.20 | 0.20 | 0.10 | 0.14 | 0.12 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.54 | 1.50 | 1.34 | 1.41 | 1.36 |
| Debt Service Coverage Ratio | 0.81 | 0.68 | 1.85 | 1.00 | 1.16 |
| Interest Coverage Ratio | 8.54 | 34.30 | 44.64 | 39.48 | 103.26 |
| Debt to Market Cap | 0.10 | 0.07 | 0.02 | 0.07 | 0.04 |
| Interest Debt Per Share | 77.51 | 67.98 | 28.97 | 39.28 | 37.38 |
| Net Debt to EBITDA | 1.11 | 1.18 | 0.43 | 0.93 | 0.76 |
| Profitability Margins | |||||
| Gross Profit Margin | 45.06% | 71.81% | 71.16% | 68.60% | 71.76% |
| EBIT Margin | 10.72% | 10.94% | 10.61% | 7.74% | 11.07% |
| EBITDA Margin | 15.06% | 14.82% | 14.68% | 12.32% | 16.18% |
| Operating Profit Margin | 10.89% | 40.49% | 40.27% | 35.04% | 34.51% |
| Pretax Profit Margin | 9.45% | 10.60% | 10.14% | 6.27% | 11.79% |
| Net Profit Margin | 9.19% | 8.74% | 9.89% | 6.05% | 9.82% |
| Continuous Operations Profit Margin | 9.13% | 8.72% | 9.89% | 6.05% | 9.82% |
| Net Income Per EBT | 97.24% | 82.50% | 97.47% | 96.44% | 83.30% |
| EBT Per EBIT | 86.75% | 26.17% | 25.19% | 17.90% | 34.16% |
| Return on Assets (ROA) | 7.70% | 7.51% | 9.55% | 5.53% | 7.31% |
| Return on Equity (ROE) | 11.89% | 11.24% | 12.78% | 7.83% | 9.95% |
| Return on Capital Employed (ROCE) | 12.97% | 50.40% | 50.26% | 43.57% | 33.87% |
| Return on Invested Capital (ROIC) | 10.40% | 33.84% | 44.94% | 36.74% | 25.21% |
| Return on Tangible Assets | 7.96% | 7.51% | 9.55% | 5.53% | 7.48% |
| Earnings Yield | 5.18% | 3.31% | 3.11% | 3.51% | 3.57% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.01 | 4.77 | 6.08 | 5.38 | 6.54 |
| Payables Turnover | 4.83 | 2.14 | 2.44 | 2.61 | 2.12 |
| Inventory Turnover | 1.61 | 0.82 | 1.09 | 1.20 | 0.93 |
| Fixed Asset Turnover | 2.11 | 1.99 | 2.03 | 1.88 | 1.34 |
| Asset Turnover | 0.84 | 0.86 | 0.97 | 0.91 | 0.74 |
| Working Capital Turnover Ratio | 4.02 | 4.04 | 4.30 | 4.68 | 4.22 |
| Cash Conversion Cycle | 224.44 | 349.88 | 244.56 | 231.48 | 275.87 |
| Days of Sales Outstanding | 72.87 | 76.58 | 60.06 | 67.89 | 55.80 |
| Days of Inventory Outstanding | 227.11 | 444.06 | 333.99 | 303.40 | 392.16 |
| Days of Payables Outstanding | 75.54 | 170.76 | 149.49 | 139.81 | 172.09 |
| Operating Cycle | 299.98 | 520.64 | 394.05 | 371.29 | 447.96 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 35.38 | 4.48 | 40.86 | 36.83 | 28.10 |
| Free Cash Flow Per Share | 13.26 | -24.20 | 24.20 | 14.27 | 6.45 |
| Dividend Paid and CapEx Coverage Ratio | 1.07 | 0.11 | 1.66 | 1.13 | 0.79 |
| Capital Expenditure Coverage Ratio | 1.60 | 0.16 | 2.45 | 1.63 | 1.30 |
| Operating Cash Flow Coverage Ratio | 0.49 | 0.07 | 1.57 | 1.00 | 0.77 |
| Operating Cash Flow to Sales Ratio | 0.09 | 0.01 | 0.13 | 0.13 | 0.10 |
| Free Cash Flow Yield | 2.00% | -2.70% | 2.40% | 2.88% | 0.87% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 19.32 | 30.22 | 32.20 | 28.53 | 27.98 |
| Price-to-Sales (P/S) Ratio | 1.77 | 2.64 | 3.18 | 1.73 | 2.75 |
| Price-to-Book (P/B) Ratio | 2.30 | 3.40 | 4.12 | 2.23 | 2.78 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 50.01 | -37.06 | 41.69 | 34.78 | 115.04 |
| Price-to-Operating Cash Flow Ratio | 18.75 | 200.40 | 24.69 | 13.48 | 26.39 |
| Price-to-Earnings Growth (PEG) Ratio | 1.23 | -5.74 | 0.40 | -0.83 | -0.51 |
| Enterprise Value Multiple | 12.90 | 19.00 | 22.13 | 14.94 | 17.74 |
| Enterprise Value | 142.64B | 187.96B | 202.25B | 104.03B | 152.33B |
| EV to EBITDA | 12.90 | 19.00 | 22.13 | 14.94 | 17.74 |
| EV to Sales | 1.94 | 2.82 | 3.25 | 1.84 | 2.87 |
| EV to Free Cash Flow | 54.72 | -39.52 | 42.51 | 37.08 | 120.22 |
| EV to Operating Cash Flow | 20.51 | 213.67 | 25.18 | 14.37 | 27.58 |
| Tangible Book Value Per Share | 273.83 | 264.01 | 245.12 | 222.34 | 258.58 |
| Shareholders’ Equity Per Share | 288.72 | 264.09 | 245.12 | 222.34 | 266.46 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | 0.18 | 0.03 | 0.04 | 0.17 |
| Revenue Per Share | 373.68 | 339.44 | 316.88 | 287.57 | 269.93 |
| Net Income Per Share | 34.33 | 29.68 | 31.33 | 17.40 | 26.50 |
| Tax Burden | 0.97 | 0.82 | 0.97 | 0.96 | 0.83 |
| Interest Burden | 0.88 | 0.97 | 0.96 | 0.81 | 1.06 |
| Research & Development to Revenue | 0.00 | 0.08 | 0.08 | 0.13 | 0.16 |
| SG&A to Revenue | 0.34 | 0.23 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.03 | 0.15 | 1.30 | 2.04 | 0.89 |
Currency in INR
